Longeveron price target lowered to $3 from $10 at Roth Capital

Roth Capital lowered the firm’s price target on Longeveron (LGVN) to $3 from $10 and keeps a Buy rating on the shares. The firm’s price target cut reflects Q2 results and the dilutive equity financing earlier this week, though Longeveron remains an underappreciated firm despite its first-mover advantage in HLHS, or Hypoplastic Left Heart Syndrome, the analyst tells investors in a research note.